Who We Are
We are a biopharmaceutical company focused on discovering, developing and commercializing novel drugs that target G protein-coupled receptors (GPCRs) to address unmet medical needs.
“Our team at Arena is driven to deliver best-in-class pharmaceuticals that address unmet medical needs and improve the health of patients. We are pleased to announce BELVIQ’s US launch as we continue innovating to advance additional drug candidates through our validated platform.”
-Jack Lief, President and Chief Executive Officer
BELVIQ is approved by the US Food and Drug Administration and will be available in the US only after its Schedule IV designation is effective on June 7, 2013.